Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Biomira updates progress of Theratope and BLP25

May 27, 2002

Antisense oligonucleotide targeting TGF-beta2 shows promise for malignant glioma, other solid tumors

May 24, 2002

Zycos and Pharmexa sign cancer vaccine formulation agreement

May 17, 2002

Remitogen enters phase I solid tumor trial

May 16, 2002

FDA requests Provenge composition information from Dendreon

May 9, 2002

IL-13-PE38 granted fast track designation for malignant glioma

May 7, 2002

Gene-modified autologous tumor cell vaccine tested in patients with metastatic renal cell carcinoma

May 6, 2002

CancerVax puts hold on new patient enrollment in Canvaxin trial

May 3, 2002

Patient enrollment begins in pivotol Phase III Oncophage for melanoma study

May 3, 2002

Avicine set to enter phase III in pancreatic cancer

May 3, 2002

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...